一次剂量活减弱的YF17D载体的SARS-CoV-2疫苗候选
Lorena Sanchez-Felipe1,2, Thomas Vercruysse1,3, Sapna Sharma1,2
1KU Leuven Department of Microbiology, Immunology and Transplantation, Rega Institute, Virology and Chemotherapy, Molecular Vaccinology and Vaccine Discovery, KU Leuven, Leuven, Belgium.
Nature
|December 1, 2020
概括
一种新型疫苗候选物YF-S0使用黄热病病毒载体来表达SARS-CoV-2抗原. 这种疫苗显示出出色的安全性和有效性,在动物模型中迅速诱导对COVID-19的保护性免疫力.
科学领域:
- 疫苗学
- 病毒学
- 免疫学
背景情况:
- 由于COVID-19的流行,需要快速开发安全有效的疫苗.
- 活体减弱病毒载体为疫苗开发提供了一个有前途的平台.
研究的目的:
- 开发和评估针对SARS-CoV-2的新型候选疫苗 (YF-S0).
- 在临床前模型中评估YF-S0的安全性,免疫性和有效性.
主要方法:
- 开发一种活衰减的黄热病17D疫苗载体,表达一种预注射SARS-CoV-2尖端抗原.
- 评估疫苗安全性,抗体反应,细胞免疫力以及对子,老鼠和的SARS-CoV-2挑战的保护.
主要成果:
- 在动物模型中,YF-S0表现出极好的安全性.
- 该疫苗诱导了高水平的SARS-CoV-2中和抗体以及对SARS-CoV-2和黄热病病毒的保护性免疫力.
- 一次剂量很快就能对仓鼠的肺部疾病产生保护作用.
结论:
- YF-S0是一种强大的SARS-CoV-2疫苗候选剂,具有快速的保护性免疫力.
- 疫苗能够引起强大的幽默和细胞免疫反应,因此需要进一步的临床开发.
更多相关视频
10:58Production of E. coli-expressed Self-Assembling Protein Nanoparticles for Vaccines Requiring Trimeric Epitope Presentation
Published on: August 21, 2019
7.8K
12:09Protocol for Recombinant RBD-based SARS Vaccines: Protein Preparation, Animal Vaccination and Neutralization Detection
Published on: May 2, 2011
43.2K
相关概念视频
01:30Cancer Vaccines
677
Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
677
01:51Vaccinations
49.6K
Overview
49.6K